Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)
SEK 3.42
(-2.29%)
SEK 3.42
(-2.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -14.07 Million SEK | 28.13% |
| 2023 | -19.58 Million SEK | -33.54% |
| 2022 | -14.66 Million SEK | -160.93% |
| 2021 | -5.62 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.58 Million SEK | -47.93% |
| 2024 Q1 | -3.09 Million SEK | 35.36% |
| 2024 Q4 | 1.89 Million SEK | 122.89% |
| 2024 Q3 | -8.29 Million SEK | -81.02% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q2 | -4.86 Million SEK | 0.0% |
| 2023 FY | -19.58 Million SEK | -33.54% |
| 2023 Q3 | -4.18 Million SEK | 13.95% |
| 2023 Q4 | -4.79 Million SEK | -14.47% |
| 2022 FY | -14.66 Million SEK | -160.93% |
| 2021 FY | -5.62 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | -6.257% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | 63.206% |
| BioGaia AB (publ) | 440.9 Million SEK | 103.193% |
| Enzymatica AB (publ) | -48.06 Million SEK | 70.709% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | 66.351% |
| Gabather AB (publ) | -9.47 Million SEK | -48.596% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | 4.101% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | 48.738% |
| Nanexa AB (publ) | -76.62 Million SEK | 81.627% |
| ODI Pharma AB | -1.34 Million SEK | -949.313% |
| Orexo AB (publ) | -109.5 Million SEK | 87.143% |
| Probi AB (publ) | 11.32 Million SEK | 224.364% |
| Swedencare AB (publ) | 173.2 Million SEK | 108.128% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 100.302% |
| Toleranzia AB | -7.89 Million SEK | -78.406% |
| Vivesto AB | -356.71 Million SEK | 96.053% |